Autres langues OneSource Specialty Pharma Limited

Actions

ONESOURCE

INE013P01021

Recherche biotechnologique et médicale

Marché Fermé - NSE India S.E. Autres places de cotation 13:05:09 31/07/2026			Varia. 5j.	Varia. 1 janv.
1 619,70 ^INR	-4,06%		-2,09%	-10,54%

24/07	OneSource Specialty Pharma Limited publie ses résultats pour le premier trimestre clos le 30 juin 2026	CI
24/07	OneSource Specialty Pharma Limited annonce des changements au sein de sa direction, effectifs au 24 juillet 2026	CI

Autres langues

27/07	Formycon And OneSource Specialty Pharma Partner To Manufacture Biosimilars
24/07	OneSource Specialty Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2026
24/07	OneSource Specialty Pharma Limited Announces Executive Changes, Effective July 24, 2026
20/07	OneSource Specialty Pharma Limited Recalls Methohexital Sodium for Injection
14/07	Formycon Ag and Onesource Specialty Pharma Limited Announce Strategic Manufacturing Partnership for Biosimilars
14/07	Morning Meeting: Trumps neuer Plan für die Straße von Hormus
14/07	Formycon Partners with OneSource Specialty Pharma for Biosimilars Manufacturing
13/05	Onesource Specialty Pharma not to pursue merger of facilities of Steriscienceat with co
13/05	Onesource Specialty Pharma March-quarter consol profit 46 million rupees
13/05	OneSource Specialty Pharma Limited Announces Resignation of Prateek Gupta as SVP & Head Technical Development, Effective May 13, 2026
13/05	OneSource Specialty Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026
04/05	OneSource Specialty Pharma Limited and Orbicular Receives Approval from Health Canada for A Generic Version of Ozempic
29/04	Dr. Reddy's Laboratories Gets Regulatory Nod to Sell Semaglutide Injection in Canada
29/04	Dr. Reddy's Laboratories Gets Regulatory Nod to Sell Semaglutide Injection in Canada
21/04	OneSource Specialty Pharma's Partner Gets US FDA Nod for Generic Version of Ozempic
21/04	Onesource Specialty Pharma says Orbicular secures tentative U.S. FDA ANDA approval for generic Ozempic
17/04	Onesource Specialty Pharma says EU-GMP certification for Unit II manufacturing facility renewed
11/02	OneSource Specialty Pharma Gets Approval to Commercialize Generic Version of Ozempic in Saudi Arabia
11/02	Onesource Specialty says Onesource-Hikma secures approval to commercialise generic Ozempic in Saudi Arabia
11/02	OneSource Specialty Pharma Limited Announces That It Has Received Saudi Food and Drug Authority Approval of Its Generic Ozempic®? (Semaglutide) in Saudi Arabia
23/01	OneSource Specialty Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025
23/01	Onesource Specialty Pharma posts Dec-quarter consol loss of 887 million rupees
11/11	OneSource Specialty Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025
04/08/25	OneSource Specialty Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2025
07/07/25	Onesource Specialty Pharma Limited Appoints Jeffrey Wong as Chief Business Officer, Effective Date Is July 7, 2025